TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Biopsy-proven breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in AIDS-risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat, carbohydrate, and protein utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative reinforcing value (RRV) of energy-dense snack foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Hot Flushes Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMPS-process skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPM-performance measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Zarit Burden Inventory (ZBI)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Progressive disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in muscle soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline the quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline the perception of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline the compliance to the prophylactic treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contact lens wear comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: completion of exercise protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Lower Extremity Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinuation of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for Dolutegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants (Pregnant Women) With Maximum Severity of Post-Baseline Emergent Hematology Toxicities: Hemoglobin
Endpoint domain: Adverse events/effects
Primary endpoint: IL-4, IL-5, IL-13, IL-17, IL-33 concentration in the Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Histamine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myelin Basic Protein concentration (MBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IgE concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of couples screened and rates for non-eligibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total number of couples screened and rates of refusal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anatomic cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of observed maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucoregulatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in latency to persistent sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of SARS-CoV-2 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and Tolerability of the investigational drug
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or absence of genetic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Care of Heart Failure Maintenance Scale (SCHFI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric mucosal visibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: How many times the app is accessed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stool consistency (Bristol Stool Chart)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspepsia Symptom Severity Index (DSSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood pressure and pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EKG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CSF endothelial marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF Alzheimer's biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in patient chest X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the modified Borg dyspnea scale after tPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep architecture correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change in biomarkers of fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in symptom ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in resting Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in aneurysmal vessel wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of donor livers preserved by OCS in a near physiologic state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of events leading to donor liver not being clinically acceptable
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of bone fill after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Disease Activity Score Based on 28-Joint Count (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPA Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear growth (change in height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maslach Burnout Inventory- General Survey (MBI-GS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Standardized measure of health outcome (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Severity of anemia in patients with liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relationship between IVC measurements, eRAP and BNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Electronic-ETDRS visual acuity testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of grade 3+
Endpoint domain: Adverse events/effects
Primary endpoint: real time performance in the operating room
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: modified Rankin Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Survival after developing spinal metastases
Endpoint domain: Mortality/survival
Primary endpoint: The 6-Minutes Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about CVD and CVD risk
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes about CVD and CVD risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients wearing BACTrack sensor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mortality rate during the first year following anesthesia
Endpoint domain: Mortality/survival
Primary endpoint: Number of reanimation alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the semaglutide concentration time curve (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed semaglutide concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Female Athlete Triad
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of symptoms of endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Prothrombin Time/international normalized ratio (PT/INR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in aPTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Thromboelastogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-CEUS quantitative parameters for characterizing FLLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of CT-011
Endpoint domain: Adverse events/effects
Primary endpoint: Serum miR-122 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: DILI (Drug-Induced Liver Injury)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Hepatic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of patients undergoing partial nephrectomy
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Observed Maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on central and peripheral small airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Confirmed Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Confirmed Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Joint position sense test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Summed Pain Intensity (SPI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal antibiotic treatment adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Amniotic fluid leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: All Hospital Episodes Related to Treatment for Atrial Arrhythmia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Severe (NCI CTCAE Grade 3/4/5) TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Overall Survival (OS) at 12 Months for Participants With ndDIPG and Recurrent HGG (rHGG)
Endpoint domain: Mortality/survival
Primary endpoint: Total linear distance in mm covered by gel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface area actually covered by gel (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methotrexate Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration of Methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of Methotrexate in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematological effects (complete and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: biofilm density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of leakage under the skin protector
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HDL-Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurological function stabilization or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in skeletal muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relative genetic expression of NF-KB1 and IKK epsilon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 Year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: 2 Year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gaps in therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of patients with MDS
Endpoint domain: Mortality/survival
Primary endpoint: Discomfort Intolerance Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: The Distress Tolerance Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fibromyalgia Impact Questionnaire - Revised
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stigma Scale for Chronic Illness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circulating progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from body mass index (BMI) at 12 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral availability of mGluR5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Viral Response 12 Weeks After Cessation of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit rates after 8 weeks post-target quit date
Endpoint domain: Mortality/survival
Primary endpoint: Orthodontic tooth movement Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) - Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) - Glycopyrronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) - Formoterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC 0-12) - Budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC 0-12) - Glycopyrronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on the Short-Form 36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Uterine Artery Indices Completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Patients With Umbilical Artery Indices Completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Systolic(S)/Diastolic(D) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Placental Pathology Indicating Chronic Villitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Good outcome at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Breast cancer risk prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experienced a Medically Attended Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Seroconversion for SARS-CoV-2 Receptor-Binding Domain (RBD) of Spike Protein Antibodies (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Precision and agreement of TOF-ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: toxicity profile of oral MRX-1024
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetic parameters of oral MRX-1024
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst of the Pain Scores for the Week Following the First Cycle of Paclitaxel Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum of the Average Pain Scores Over the Period From Treatment Initiation to Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum 25(OH)D response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AMH marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Health status and health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean number of days interacting with cardiovascular risk service
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean number of contacts with a pharmacist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Pregnancy Following Emergency Contraception
Endpoint domain: Mortality/survival
Primary endpoint: Cmax for Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24h for Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Ginkgolides Meglumine Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau,ss for Ginkgolides Meglumine Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EORTC QLQ C30 questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: QoL questionnaire DLQI questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % of enrolled subjects experiencing a specific adverse event according to NCI CTC-AE version 4.0
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of Faecal immunochemical test and urine volatile markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Steady state AUC(0-24) of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ct (approximate Cmin) of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dizziness Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean distinguishable frameshift peptide protein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of syllables stuttered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent change in non-inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dual-task cost on gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting Toxicities (DLT) and/or Maximum Plasma Level > 1000 pg/mL
Endpoint domain: Adverse events/effects
Primary endpoint: Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients receiving medication assisted treatment for opioid use disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes